Needham Maintains Their Hold Rating on Regulus (RGLS)


In a report released today, Alan Carr from Needham maintained a Hold rating on Regulus (RGLS). The company’s shares closed last Friday at $0.50, close to its 52-week low of $0.42.

According to TipRanks.com, Carr is a 3-star analyst with an average return of 1.5% and a 43.0% success rate. Carr covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Lexicon Pharmaceuticals, and Crispr Therapeutics AG.

Currently, the analyst consensus on Regulus is a Moderate Buy with an average price target of $1.25.

See today’s analyst top recommended stocks >>

Based on Regulus’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.95 million. In comparison, last year the company earned revenue of $18K and had a GAAP net loss of $5.02 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts